PDCD1 and posterior cortical atrophy: A comprehensive analysis of publicly available data on PD-1/PD-L1 inhibitor monotherapy in PCa demonstrates that PD-1 inhibitors (pembrolizumab, nivolumab; n = 319) (118, 139, 141) were associated with frequent adverse events including gastrointestinal toxicities (nausea, diarrhea, decreased appetite), skin and subcutaneous tissue disorders (maculopapular rash, pruritus, rash), and systemic conditions (fatigue, asthenia, weight loss).